Study finds bone density loss associated with levothyroxine

Levothyroxine, the second most commonly prescribed medication among older adults in the U.S., may be associated with bone loss, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA).

Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda – Biotech Investments

EQS-News: Formycon AG / Key word(s): Study/Miscellaneous Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda 13.06.2024 / 07:31

June 14, 2024

Immunology biotech Alumis secures $250M in shrunken IPO

Alumis, an immunology drug developer on the cusp of Phase 3, will go public Friday in a smaller IPO than it originally projected. The Bay

June 29, 2024

Lantidra wins FDA approval as first-ever type 1 diabetes cell therapy – Pharmaceutical Technology

Cell therapies such as Lantidra could make type 1 diabetes much easier to manage – with or without insulin. Credit: Shutterstock / goffkein.pro. The US

June 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.